.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Baxter
Julphar
Federal Trade Commission
Colorcon
Dow
US Army
AstraZeneca
Harvard Business School
McKesson

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Compositions including triciribine and methods of use thereof
Abstract: This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Inventor(s): Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL)
Assignee: University of Florida (Tampa, FL)
Application Number:14/514,311
Patent Claims:1. A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising: a. confirming whether the subject has a tumor or cancer that overexpresses AKT kinase and administering to said subject: i. at least one compound of formula I selected from the group consisting of the following compounds: ##STR00025## wherein each R.sub.2', R.sub.3', and R.sub.5' is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I; wherein R.sub.2', R.sub.3' or R.sub.5' is independently H or mono-, di- or tri-phosphate; wherein R.sup.x and R.sup.y are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and wherein R.sub.1 and R.sub.2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl; ii. trastuzumab or a salt thereof; and iii. a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein the compound of formula I is triciribine phosphate.

3. The method of claim 1, wherein the compound of formula I is present in an amount of at least 20 mg/m.sup.2.

4. The method of claim 1, wherein the compound of formula I is present in an amount of at least 10 mg/m.sup.2.

5. The method of claim 1, wherein the administration is parenteral administration.

6. The method of claim 1, wherein the parenteral administration is intravenous administration.

7. The method of claim 1, wherein administration is oral administration.

8. The method of claim 1, suitable for topical administration.

9. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 1 mg to about 1000 mg.

10. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 100 mg to about 500 mg.

11. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount from about 200 mg to about 450 mg.

12. The method of claim 1, wherein the trastuzumab or salt thereof is present in an amount of about 440 mg.

13. The method of claim 1, wherein the administration of a compound of formula I and trastuzumab or a salt thereof is concurrently administered.

14. The method of claim 1, wherein the administration of a compound of formula I is following by the administration of trastuzumab or a salt thereof.

15. The method of claim 1, wherein the administration of trastuzumab or a salt thereof is followed by the administration of a compound of formula I.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe University of Florida (Tampa, FL) Cheng; Jin Q. (Tampa, FL), Sebti; Said M. (Tampa, FL) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2005228410Oct 13, 2005
Canada2561513Oct 13, 2005
Canada2724246Nov 19, 2009
China1984663Jun 20, 2007
Denmark2574341Jun 26, 2017
European Patent Office1737472Aug 13, 2014
European Patent Office1737472Jan 03, 2007
European Patent Office1737472Sep 01, 2010
European Patent Office2300055Mar 30, 2011
European Patent Office2574341Apr 03, 2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Dow
McKinsey
Colorcon
Novartis
Chinese Patent Office
Teva
Accenture
Healthtrust
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot